caa a22 4500 445883502 CHVBK 20180317145552.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s10157-011-0465-6 doi (NATIONALLICENCE)springer-10.1007/s10157-011-0465-6 Rituximab and minimal change nephrotic syndrome: a therapeutic option [Elektronische Daten] [Takashi Takei, Kosaku Nitta] Minimal change nephrotic syndrome (MCNS) usually responds to steroids but frequently relapses, requiring additional treatment with immunosuppressive agents. Rituximab is a chimeric murine/human monoclonal immunoglobulin G1 antibody that targets CD20, a B-cell differentiation marker. B-cell recovery begins at approximately 6months following the completion of treatment. Rituximab has a beneficial effect, with the sustained remission or reduction of proteinuria in patients with steroid-dependent MCNS. Relapses are thought to be associated with an increase in CD19 cells. The mean serum half-life of rituximab was reported to be 10-15days in patients with steroid-dependent nephrotic syndrome. Only infusion reactions, such as rash and chills, occurred after single-dose rituximab infusion and can be managed by pre-medication or infusion rate adjustments. Even though severe adverse effects of rituximab are not expected, physicians must be aware of potentially life-threatening adverse effects. Controlled randomized trials that include adult patients with steroid-dependent or steroid-resistant MCNS are required to prove the efficacy and safety of rituximab and to evaluate the cost-effectiveness of rituximab treatment. Japanese Society of Nephrology, 2011 Rituximab nationallicence Minimal change nephrotic syndrome nationallicence Relapse nationallicence Treatment nationallicence Immunosuppression nationallicence Takei Takashi Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-866, Tokyo, Japan aut Nitta Kosaku Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-866, Tokyo, Japan aut Clinical and Experimental Nephrology Springer Japan 15/5(2011-10-01), 641-647 1342-1751 15:5<641 2011 15 10157 https://doi.org/10.1007/s10157-011-0465-6 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-011-0465-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Takei Takashi Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-866, Tokyo, Japan aut NATIONALLICENCE 700 1- Nitta Kosaku Department of Medicine, Kidney Center, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, 162-866, Tokyo, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/5(2011-10-01), 641-647 1342-1751 15:5<641 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer